Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H10O4 |
| Molecular Weight | 182.1733 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCOC(=O)C1=CC=CC=C1O
InChI
InChIKey=LVYLCBNXHHHPSB-UHFFFAOYSA-N
InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2
DescriptionSources: http://www.salonpas.sg/products/list003.htmlCurator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?dr:D01557
Sources: http://www.salonpas.sg/products/list003.html
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?dr:D01557
Glycol Salicylate is a nonsteroidal antiinflammatory drug, it is an ingredient of many rubefacient creams and sprays for the relief of aches, pains and stiffness in muscles joints and tendons. It is an analgesic and anti-inflammatory agent, used topically. It is also included in preparations for soothing haemorrhoids. Glycol Salicylate is a component of Salonsip Gel Patch. Salonsip Gel Patch, manufactured by Hisamitsu Pharmaceutical Co., Inc. of Tosu City, Japan, consists of Glycol Salicylate 1.25%, l-menthol 1.00%, Tocopherol Acetate 1.0%, dl-camphor 0.1%.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Salonsip Gel-Patch Approved UseFor relief of aches, pains and minor inflammations associated with:
■ muscle fatigue
■ muscle pain
■ stiff shoulder
■ simple backache
■ bruises
■ sprains
■ strains
■ arthritis
■ minor frostbite |
|||
| Palliative | Percutalgine Approved UseFor treatment of benign joint conditions such as mild tendinitis, small joint arthritis and sprains. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 % 1 times / day single, topical Studied dose Dose: 10 %, 1 times / day Route: topical Route: single Dose: 10 %, 1 times / day Sources: |
healthy, 47 years Health Status: healthy Age Group: 47 years Sex: M Sources: |
Other AEs: Contact dermatitis... Other AEs: Contact dermatitis Sources: |
5 % multiple, topical Studied dose |
unhealthy, 64 years |
Other AEs: Contact dermatitis... |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
Disc. AE: Urticaria, Skin irritation... Other AEs: Redness, Itching... AEs leading to discontinuation/dose reduction: Urticaria (0.4%) Other AEs:Skin irritation (0.4%) Redness (1.7%) Sources: Itching (1.7%) Urticaria (1.7%) |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
Disc. AE: Urticaria, Redness... AEs leading to discontinuation/dose reduction: Urticaria (0.4%) Sources: Redness (0.4%) Allergic reaction (0.4%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Contact dermatitis | 10 % 1 times / day single, topical Studied dose Dose: 10 %, 1 times / day Route: topical Route: single Dose: 10 %, 1 times / day Sources: |
healthy, 47 years Health Status: healthy Age Group: 47 years Sex: M Sources: |
|
| Contact dermatitis | 5 % multiple, topical Studied dose |
unhealthy, 64 years |
|
| Skin irritation | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Urticaria | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Itching | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Redness | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Urticaria | 1.7% | 12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Allergic reaction | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Redness | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
| Urticaria | 0.4% Disc. AE |
12.5 mg 5 times / day multiple, topical Studied dose Dose: 12.5 mg, 5 times / day Route: topical Route: multiple Dose: 12.5 mg, 5 times / day Sources: |
unhealthy, mean age 30.8 years Health Status: unhealthy Age Group: mean age 30.8 years Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synergetic analgesic effect of the combination of arnica and hydroxyethyl salicylate in ethanolic solution following cutaneous application by transcutaneous electrostimulation. | 2003 |
|
| Contact dermatitis from anti-inflammatory gel containing hydroxyethyl salicylate. | 2002-08 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.salonpas.sg/products/list003.html
Adults and children 12 years of age and over:
clean and dry affected area. Remove from backing film and apply to affected area not more than 3 to 4 times daily. Remove after at most 8 hours.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
87-28-5
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
3269
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
86541
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
201-737-2
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
C020904
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
72097
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
26051
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB11323
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
3I1VBB7AXH
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
SUB13999MIG
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
6880
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
DTXSID4048987
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
3I1VBB7AXH
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
100000089635
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | |||
|
m5805
Created by
admin on Mon Mar 31 17:45:11 GMT 2025 , Edited by admin on Mon Mar 31 17:45:11 GMT 2025
|
PRIMARY | Merck Index |
SUBSTANCE RECORD